Issue 2/2016
Content (8 Articles)
Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain
Yi Zheng, Xijing Chen, Leslie Z. Benet
Alternative Sampling Strategies for Cytochrome P450 Phenotyping
Pieter M. M. De Kesel, Willy E. Lambert, Christophe P. Stove
Challenges Associated with Route of Administration in Neonatal Drug Delivery
Matthew W. Linakis, Jessica K. Roberts, Anita C. Lala, Michael G. Spigarelli, Natalie J. Medlicott, David M. Reith, Robert M. Ward, Catherine M. T. Sherwin
Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
Sivi Ouwerkerk-Mahadevan, Jan Snoeys, Monika Peeters, Maria Beumont-Mauviel, Alexandru Simion
Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
Eef Hoeben, Willem De Winter, Martine Neyens, Damayanthi Devineni, An Vermeulen, Adrian Dunne
Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants
Ivo P. Nnane, Alexei H. Plotnikov, Gary Peters, Maureen Johnson, Clare Kojak, Apinya Vutikullird, Jay Ariyawansa, Ronald De Vries, Brian E. Davies
Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions
Christophe Boetsch, Neil Parrott, Stephen Fowler, Agnes Poirier, Dominik Hainzl, Ludger Banken, Meret Martin-Facklam, Carsten Hofmann
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
Lisette Binkhorst, Marjolein Bannink, Peter de Bruijn, Jan Ruit, Helga Droogendijk, Robbert J. van Alphen, Tilly D. den Boer, Mei Ho Lam, Agnes Jager, Teun van Gelder, Ron H. J. Mathijssen